Gene Therapy for Prostate Cancer That Returns After Radiation Therapy

Sponsor

Simon Hall (Other)

Overall Status

Withdrawn

CT.gov ID

NCT00110526

Collaborator

U.S. Army Medical Research and Development Command (U.S. Fed)

Enrollment

Arm

Duration (Months)

Study Details

Study Description

Brief Summary

The purpose of this research study is to test a new treatment for prostate cancer. We have been exploring the use of cytokine (immune stimulating) gene therapy by directly injecting a virus which produces a cytokine called interleukin-12 (IL-12) into the prostate gland to control tumor growth. We propose to explore the use of adenovirus-mediated human interleukin-12 (Ad.hIL-12) in patients with recurrent non-metastatic prostate cancer following radiation therapy in a Phase I trial. Participants will be placed in rising dose groups with the primary endpoint of learning the maximum dose that can safely be given by injection directly into the prostate gland. Toxicity will be determined through physical examination, laboratory values, and blood levels of cytokines. Evidence of an immune response against prostate proteins will also be monitored. If the treatment works, the cancer will shrink or not grow. This will be monitored by prostate specific antigen (PSA) levels in the blood. However, we do not know if this treatment will be effective. If the PSA continues to rise after treatment, participants will be taken off study and offered other treatment. There is no compensation for participation in this research study. There will be no charge for the treatment with gene therapy or the monitoring associated with this research study. Monitoring will occur in a specially designated clinical research center.

Condition or Disease	Intervention/Treatment	Phase
Prostatic Neoplasms Neoplasm Recurrence, Local	Genetic: Ad.hIL-12	Phase 1

Detailed Description

Patients with radiorecurrent prostate cancer have few viable treatment options, both in terms of efficacy and morbidity. Local therapies fail even in highly selected patients due to locally advanced disease, microscopic metastases, and a worsening of the biology of cancer cells. Furthermore, attempts at salvage local treatments have the complications of incontinence, impotence and in some cases unremitting penile pain. Pre-clinical studies in a mouse model of prostate cancer have noted the potential benefit of adenovirus-mediated gene therapy to deliver IL-12 in this clinical scenario. This treatment was able to significantly growth suppress the injected tumor to prolong survival and reduce the number of pre-established metastases. The mechanisms underlying this activity involved both innate immunity (neutrophils and natural killer [NK] cells) and acquired immunity ( T cells) and enhanced expression of Fas to further sensitize Fas/Fas ligand (FasL) killing.

This is a Phase I study. Therefore, the primary objective is finding the Maximum Tolerated Dose. Within this realm will be monitoring of pro-inflammatory cytokines. Secondary aspects will involve correlating important mechanisms identified in the pre-clinical model: induction of T cells.

Study Design

Study Type:

Interventional

Actual Enrollment :

0 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

Phase I Trial of Adenovirus- Mediated IL-12 Gene Transduction in Patients With Radiorecurrent Prostate Cancer

Study Start Date :

Apr 1, 2005

Actual Primary Completion Date :

Apr 1, 2008

Actual Study Completion Date :

Apr 1, 2008

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Ad.hIL-12	Genetic: Ad.hIL-12 Ad.hIL-12 intraprostatic injection IND

Arm

Intervention/Treatment

Experimental: Ad.hIL-12

Genetic: Ad.hIL-12

Ad.hIL-12 intraprostatic injection IND

Outcome Measures

Primary Outcome Measures

maximum cytokine gene therapy level [after 56 weeks, every 6 months up to 15 years]
To study in a Phase I clinical trial the safety of intraprostatic injection of a replication incompetent adenovirus expressing hIL-12 in patients with radiorecurrent prostate cancer

Secondary Outcome Measures

serum pro-inflammatory cytokines levels [up to 15 years]
To assess serum levels of pro-inflammatory cytokines before and after vector injection and will continue every 3 days until normalized
To assess T cell responses pre and post-IL-12 treatment against prostate antigens [Day 7 post vector injection]
Day 7,14,21 and 28 post vector injection
To assess T cell responses pre and post-IL-12 treatment against prostate antigens [Day 14 post vector injection]
Day 7,14,21 and 28 post vector injection
To assess T cell responses pre and post-IL-12 treatment against prostate antigens [Day 21 post vector injection]
Day 7,14,21 and 28 post vector injection
To assess T cell responses pre and post-IL-12 treatment against prostate antigens [Day 28 post vector injection]
Day 7,14,21 and 28 post vector injection
To assess changes in PSA levels as a surrogate marker for prostate cancer following Ad.hIL-12 gene therapy [1 week after vector injection]
1,2,4,6 and 8 weeks after vector injection
To assess changes in PSA levels as a surrogate marker for prostate cancer following Ad.hIL-12 gene therapy [2 weeks after vector injection]
1,2,4,6 and 8 weeks after vector injection
To assess changes in PSA levels as a surrogate marker for prostate cancer following Ad.hIL-12 gene therapy [4 weeks after vector injection]
1,2,4,6 and 8 weeks after vector injection
To assess changes in PSA levels as a surrogate marker for prostate cancer following Ad.hIL-12 gene therapy [6 weeks after vector injection]
1,2,4,6 and 8 weeks after vector injection
To assess changes in PSA levels as a surrogate marker for prostate cancer following Ad.hIL-12 gene therapy [8 weeks after vector injection]
1,2,4,6 and 8 weeks after vector injection

Eligibility Criteria

Criteria

Ages Eligible for Study:

40 Years to 75 Years

Sexes Eligible for Study:

Male

Accepts Healthy Volunteers:

Inclusion Criteria:

A local recurrence of prostate cancer (in or next to gland) following treatment by radiation therapy (either external beam or seed implantation)
Rising PSA (Prostate Specific Antigen) on at least three occasions separated by two weeks
Ultrasound guided biopsy to diagnose recurrent disease within the prostate
No evidence of prostate cancer that has spread on bone scan or Computed Tomography (CT) scan
No hormone therapy at time of enrollment to the research study

Exclusion Criteria:

Radical prostatectomy for treatment of prostate cancer
Detectable spread of prostate cancer on bone or CT scan
Immunosuppressive medication within two months of the study
Acute infection (any bacterial, viral, fungal infection requiring specific therapy)
HIV disease
Other significant medical or psychiatric conditions which pose high risk for an investigational study